Formation | 1998 |
---|---|
Type | Non-profit organization |
Legal status | Foundation |
Headquarters | Nyon, Switzerland |
Coordinates | 46°23′02.30″N6°14′14.27″E / 46.3839722°N 6.2372972°E |
Region served | Global |
President | Prof. Cyrus Cooper |
Key people | Philippe Halbout (CEO) |
Main organ | Board of Directors |
Website | www.osteoporosis.foundation |
The International Osteoporosis Foundation (IOF), headquartered in Nyon, Switzerland, is a non-governmental organization (NGO) founded in 1998. It was formed from the merger of the European Foundation for Osteoporosis, founded in 1987, and the International Federation of Societies on Skeletal Diseases. [1] The foundation functions as a global alliance of individuals and organizations concerned with the prevention, diagnosis and treatment of osteoporosis and musculoskeletal bone disease. The goal of the Foundation is to increase the early detection of osteoporosis and related musculoskeletal diseases, as well as to improve the treatment of these conditions through international collaboration among national healthcare systems and governments. [2] The Foundation is the largest global NGO dedicated to osteoporosis and musculoskeletal diseases.
Members of IOF are divided into a committee of 266 National Societies, a committee of 163 Scientific Advisors, and a committee of Corporate Advisors. The current president of IOF is Professor Cyrus Cooper. [3] [4]
IOF is a member of the Non Communicable Disease (NCD) Alliance as of 2015. [5]
IOF publishes the following journals:
The International Osteoporosis Foundation organises the annual World Osteoporosis Day, observed internationally on October 20. [10] The day is dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related diseases of bones, muscles and joints. [11] [12]
The Capture the Fracture (CTF) [13] program was created by IOF in 2012 to promote secondary fracture prevention through best practice framework guidance and recognition of Fracture Liaison Services [14] around the World. 555 Fracture Liaisons Services (FLS) have been established in 47 countries as part of the CTF program. The Map of Best Practice, [15] established as part of the CTF program, gives recognition to FLS by grading their level of service. The excellence obtained by the FLS is designated as gold, silver or bronze.[ citation needed ]
Members of the IOF Committee of Scientific Advisors address key subjects in 13 Scientific Working Groups, [16] and publish consensus statements, position papers, [17] reviews and guidelines. Topics currently being studied include adherence, bone and cancer, bone and diabetes, epidemiology/quality of life, fracture care and secondary fracture prevention, therapeutic targets, HR-pQCT High Resolution Peripheral Quantitative Computer Tomography, bone marker standards, chronic inflammation and bone structure, Menopausal Hormone Therapy (MHT), sarcopenia and impaired mobility, and skeletal rare diseases.[ citation needed ]
Calcium is essential for building and maintaining healthy bones at all ages. The IOF Calcium Calculator [18] is a simple calculator to enable individuals to assess whether they are consuming enough calcium as part of a regular diet.
The IOF Osteoporosis Risk Check [19] enables people to understand the status of bone health through a series of simple questions on family history and personal clinical risk factors.
Launched in March 2017 with a call for ‘No more broken bones’, the IOF Global Patient Charter [20] was developed in cooperation with osteoporosis patient societies worldwide. It seeks to drive global action for improved osteoporosis prevention and fracture patient care. The Charter calls on healthcare authorities to address the needs of millions of osteoporosis patients worldwide, who should have the right to diagnosis, care, involvement, and support.[ citation needed ]
The International Osteoporosis Foundation was established in 1998 with the merger of the European Foundation for Osteoporosis (EFFO) and the International Federation of Societies on Skeletal Diseases (IFSSD). [21] In 2008 IOF was granted Roster Consultative Status with the United Nations Economic and Social Council. [22]
Since 2010, IOF and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) [23] jointly organize the annual World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO). [24] The first WCO was held in 2000 in Chicago, Illinois and was formerly run by the IOF secretariat. Since 2010, there have been 11 WCO congresses organized in collaboration with ESCEO.
In addition to the annual WCO congress, IOF also hosts regional meetings and has organized 9 regional meetings since 2010 across Latin America, Middle East & Africa, and Asia Pacific. [25]
Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Onset can be gradual or sudden.
Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural deterioration of bone tissue leading to bone fragility, and consequent increase in fracture risk. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the vertebrae in the spine, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. After the broken bone heals, the person may have chronic pain and a decreased ability to carry out normal activities.
Rheumatology is a branch of medicine devoted to the diagnosis and therapy of rheumatic diseases. Physicians who have undergone formal training in rheumatology are called rheumatologists. Rheumatologists deal mainly with immune-mediated disorders of the musculoskeletal system, soft tissues, autoimmune diseases, vasculitides, and inherited connective tissue disorders.
Osteoarthritis (OA) is a type of degenerative joint disease that results from breakdown of joint cartilage and underlying bone. The most common symptoms are joint pain and stiffness. Usually the symptoms progress slowly over years. Initially they may occur only after exercise but can become constant over time. Other symptoms may include joint swelling, decreased range of motion, and, when the back is affected, weakness or numbness of the arms and legs. The most commonly involved joints are the two near the ends of the fingers and the joint at the base of the thumbs; the knee and hip joints; and the joints of the neck and lower back. Joints on one side of the body are often more affected than those on the other. The symptoms can interfere with work and normal daily activities. Unlike some other types of arthritis, only the joints, not internal organs, are affected.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
Osteopenia, preferably known as "low bone mass" or "low bone density", is a condition in which bone mineral density is low. Because their bones are weaker, people with osteopenia may have a higher risk of fractures, and some people may go on to develop osteoporosis. In 2010, 43 million older adults in the US had osteopenia. Unlike osteoporosis, osteopenia does not usually cause symptoms, and losing bone density in itself does not cause pain.
Renal osteodystrophy/adynamic bone disease is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). The term "renal osteodystrophy" was coined in 1943, 60 years after an association was identified between bone disease and kidney failure.
Hospital for Special Surgery (HSS) is a hospital in New York City that specializes in orthopedic surgery and the treatment of rheumatologic conditions.
Bone density, or bone mineral density (BMD), is the amount of bone mineral in bone tissue. The concept is of mass of mineral per volume of bone, although clinically it is measured by proxy according to optical density per square centimetre of bone surface upon imaging. Bone density measurement is used in clinical medicine as an indirect indicator of osteoporosis and fracture risk. It is measured by a procedure called densitometry, often performed in the radiology or nuclear medicine departments of hospitals or clinics. The measurement is painless and non-invasive and involves low radiation exposure. Measurements are most commonly made over the lumbar spine and over the upper part of the hip. The forearm may be scanned if the hip and lumbar spine are not accessible.
Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by osteoclasts. It is therefore promoted as a "dual action bone agent" (DABA).
Orthopedic pathology, also known as bone pathology is a subspecialty of surgical pathology which deals with the diagnosis and feature of many bone diseases, specifically studying the cause and effects of disorders of the musculoskeletal system. It uses gross and microscopic findings along with the findings of in vivo radiological studies, and occasionally, specimen radiographs to diagnose diseases of the bones.
Senile osteoporosis has been recently recognized as a geriatric syndrome with a particular pathophysiology. There are different classification of osteoporosis: primary, in which bone loss is a result of aging and secondary, in which bone loss occurs from various clinical and lifestyle factors. Primary, or involuntary osteoporosis, can further be classified into Type I or Type II. Type I refers to postmenopausal osteoporosis and is caused by the deficiency of estrogen. While senile osteoporosis is categorized as an involuntary, Type II, and primary osteoporosis, which affects both men and women over the age of 70 years. It is accompanied by vitamin D deficiency, body's failure to absorb calcium, and increased parathyroid hormone.
Steroid-induced osteoporosis is osteoporosis arising from the use of glucocorticoids analogous to Cushing's syndrome but involving mainly the axial skeleton. The synthetic glucocorticoid prescription drug prednisone is a main candidate after prolonged intake. Bisphosphonates are beneficial in reducing the risk of vertebral fractures. Some professional guidelines recommend prophylactic calcium and vitamin D supplementation in patients who take the equivalent of more than 30 mg hydrocortisone, especially when this is in excess of three months. The use of thiazide diuretics, and gonadal hormone replacement has also been recommended, with the use of calcitonin, bisphosphonates, sodium fluoride or anabolic steroids also suggested in refractory cases. Alternate day use may not prevent this complication.
The Royal Osteoporosis Society (ROS), formerly the National Osteoporosis Society, established in 1986, is the only UK-wide charity dedicated to improving the prevention, diagnosis and treatment of osteoporosis. It is based in Camerton, Somerset, England.
World Osteoporosis Day is observed annually on 20 October, and launches a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and metabolic bone disease. Organized by the International Osteoporosis Foundation (IOF), the World Osteoporosis Day campaign is accompanied by community events and local campaigns by national osteoporosis patient societies from around the world with activities in over 90 countries.
The Australian and New Zealand Bone and Mineral Society (ANZBMS) is a not-for-profit collegiate organisation and principal professional body for scientists and clinicians involved in bone and mineral metabolism research in Australia and New Zealand.
The following outline is provided as an overview of and topical guide to trauma and orthopaedics:
Radiofrequency Echographic Multi Spectrometry (REMS) is a non-ionizing technology for osteoporosis diagnosis and for fracture risk assessment. REMS processes the raw, unfiltered ultrasound signals acquired during an echographic scan of the axial sites, femur and spine. The analysis is performed in the frequency domain. Bone mineral density (BMD) is estimated by comparing the results against reference models.
Locomotive syndrome is a medical condition of decreased mobility due to disorders of the locomotor system. The locomotor system comprises bones, joints, muscles and nerves. It is a concept put forward by three professional medical societies in Japan: the Japanese Society for Musculoskeletal Medicine, the Japanese Orthopaedic Association, and the Japanese Clinical Orthopaedic Association. Locomotive syndrome is generally found in the ageing population as locomotor functions deteriorate with age. Symptoms of locomotive syndrome include limitations in joint mobility, pain, balance disorder, malalignment and gait abnormality. Locomotive syndrome is commonly caused by chronic locomotive organ diseases. Diagnosis and assessment of locomotive syndrome is done using several tests such as the stand-up and two-step tests. The risk of having locomotive syndrome can be decreased via adequate nutrition, attainment of an exercise habit and being active.
Endocrine & Metabolism Research Institute (EMRI) is one of Tehran University of Medical Sciences research institute and a pioneering institute with a mission to combine clinical care, research and education in diabetes, endocrine and metabolic diseases.